Clincosm LogoSign in Get a demo

Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04328259
Collaborator
(none)
30
Enrollment
18
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

To assess the prevalance of non_alcoholic fatty liver diseases in inflammatory bowel disease patients and its relation to type of treatment given and disease severity

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Inflammatory bowel diseases (IBD) including Crohns disease (CD) and ulcerative colitis (UC) are chronic relapsing disorders that often require long-term therapy and follow up .

    They are recognized for their complex pathophysiology that involves innate immune system deregulation and altered microbiome in genetically predisposed individuals. Non-alcoholic fatty liver disease (NAFLD) includes a wide spectrum of disorders, ranging from hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). NAFLD patients are at high risk for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Also NAFLD is typically associated with altered metabolism and metabolic syndrome (MetS).

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals
    Anticipated Study Start Date :
    Oct 1, 2020
    Anticipated Primary Completion Date :
    Oct 1, 2021
    Anticipated Study Completion Date :
    Apr 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. the prevalance of non-alcoholic fatty liver in inflammatory bowel disease participants [one year]

      u/s will be done to all participants of inflammatory bowel disease to asses the rate of non-alcoholic fatty liver affection of all patients

    Secondary Outcome Measures

    1. the Correlation between immunosuppressive drugs and prevalance of non-alcoholic fatty liver affection in inflammatory bowel disease participants [one year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Crohn's disease (CD) patients

    • ulcerative colitis (UC) patients

    Exclusion Criteria:

    • diabetic patients

    • BMI equal and more than 30.0-34.9(class I obesity)

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Al shymaa aAdel hakm Ahmed Ali, Principal Investigator, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04328259
    Other Study ID Numbers:
    • NAFLD in patient of IBD
    First Posted:
    Mar 31, 2020
    Last Update Posted:
    May 20, 2020
    Last Verified:
    May 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:
    Liver Diseases
    Intestinal Diseases
    Inflammatory Bowel Diseases
    Fatty Liver
    Fatty Liver, Alcoholic

    Study Results

    No Results Posted as of May 20, 2020